Bear

Thanks so very much ! I wonder if indeed the Company has seen a very significant difference during BOM in event rates by statin type confirming previous synergies seen with rosuvastatin. When the BOM Trial was showing an overall 7% event rate it would not be difficult to construct a very useful model if for example the rosuvastatin group was showing 5-6% and atorvastatin 8-9% at that time . I am just speculating as to possible signals the Company may be seeing to explain the extreme confidence their actions appear to be exhibiting, especially in the context of previous trial failure. I find it hard to accept that HL would be this bold without good reason.All pure speculation on my part; all comments welcome Thanks Again Bear!